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Summary
Background.  —  The  rate  of  uncontrolled  hypertensives  aged  >80  years  is  not  well  known.  The
available literature  on  this  topic  has  used  the  threshold  <140/90  mmHg,  whereas  there  is  now
a consensus  for  a  different  target:  systolic  blood  pressure  (SBP)  <  150  mmHg.Quality  of  health
care;
Pulse  pressure
Aims. —  This  prospective  observational  population-based  study  sought  to  assess  the  frequency
and management  of  uncontrolled  hypertension  in  French  patients  aged  ≥80  years.
Methods.  —  Nine  hundred  and  seventy-one  treated  hypertensive  outpatients  were  evaluable
(204 recruited  by  cardiologists,  767  by  general  practitioners  [GPs];  mean  age  84.8  ±  3.8  years;
57.8% women).
Abbreviations: ABPM, Ambulatory blood pressure monitoring; CI, Conﬁdence interval; DBP, Diastolic blood pressure; ESC, European
ociety of Cardiology; ESH, European Society of Hypertension; GP, General practitioner; OR, Odds ratio; SBP, Systolic blood pressure; SBPM,
elf blood pressure measurement.
∗ Corresponding author. CHU de Poitiers, centre d’investigation clinique, 2, rue de la Milétrie, 86021 Poitiers, France.
E-mail address: stephanie.ragot@chu-poitiers.fr (S. Ragot).
http://dx.doi.org/10.1016/j.acvd.2014.03.002
875-2136/© 2014 Elsevier Masson SAS. All rights reserved.
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Results.  —  The  frequency  of  SBP  ≥  150  mmHg  was  36.6%  (44.6%  in  cardiologists’  patients  and
34.4% in  GPs’  patients).  The  frequency  of  satisfaction  with  SBP  ≥  150  mmHg  was  22.0%  for  car-
diologists  (32.6%  if  diastolic  blood  pressure  [DBP]  <  90  mmHg  and  9.5%  if  ≥90  mmHg;  P  =  0.008)
and 30.4%  for  GPs  (51.7%  if  DBP  <  90  mmHg  and  13.2%  if  ≥90  mmHg;  P  <  0.0001).  Non-diabetic
status (for  cardiologists)  and  DBP  <  90  mmHg  (for  cardiologists  and  GPs)  were  independent  deter-
minants of  SBP  being  considered  acceptable.  Accordingly,  in  patients  with  an  SBP  level  ≥
150 mmHg  that  was  considered  too  high,  treatment  was  reinforced  more  often  if  DBP  was
≥90 mmHg  (82.3%)  than  <90  mmHg  (68.5%).
Conclusion.  —  In  France,  hypertension  is  uncontrolled  in  more  than  one  in  three  elderly  hyper-
tensives. Physicians  are  aware  that  SBP  should  be  lowered  to  <  150  mmHg  in  patients  aged  >  80
years, but  when  the  target  is  not  reached  they  are  less  likely  to  increase  treatment  if  DBP
is <  90  mmHg.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  prévalence  de  l’hypertension  artérielle  (HTA)  non  contrôlée  chez  les  sujets
de 80  ans  ou  plus  est  mal  connue.  La  littérature  disponible  sur  ce  thème  a  utilisé  le
seuil PA  <  140/90  mmHg,  alors  qu’il  y  a  maintenant  un  consensus  pour  une  cible  différente:
PAS <  150  mmHg.
Objectifs.  — Cette  étude  observationnelle  a  pour  objectif  d’évaluer  la  prévalence  et  la  prise
en charge  de  l’HTA  non  contrôlée  des  sujets  d’âge  ≥  80  ans.
Méthodes.  — Neuf  cent  soixante  et  onze  patients  suivis  en  consultation  pour  une  HTA  traitée
ont été  évalués  (204  par  des  cardiologues,  767  par  des  médecins  généralistes  (MG)  ;  âge  moyen
84,8 ±  3,8  ans  ;  57,8  %  de  femmes).
Résultats.  — La  prévalence  d’une  PAS  ≥  150  mmHg  était  de  44,6  %  chez  les  cardiologues  et  34,4  %
en médecine  générale.  Le  taux  de  satisfaction  avec  une  PAS  ≥  150  mmHg  était  de  30,4  %  pour
les MG  et  22,0  %  pour  les  cardiologues.  L’absence  de  diabète  (pour  les  cardiologues)  et  une
PAD ≤  90  mmHg  (pour  cardiologues  et  MG)  étaient  les  déterminants  indépendants  d’une  PAS
considérée comme  acceptable.  En  conséquence,  face  à  une  PAS  ≥  150  mmHg  et  considérée
comme trop  élevée,  le  traitement  était  plus  souvent  renforcé  quand  la  PAD  était  ≥  90  mmHg
(82,3 %)  que  lorsqu’elle  était  <  90  mmHg  (68,5  %).
Conclusions.  —  En  France,  plus  d’un  hypertendu  âgé  sur  3  n’est  pas  contrôlé.  Les  médecins
savent que  la  PAS  doit  être  abaissée  en-dessous  de  150  mmHg  chez  les  plus  de  80  ans,  mais  quand
la cible  n’est  pas  atteinte,  ils  sont  malheureusement  moins  enclins  à  renforcer  le  traitement  si
la PAD  est  inférieure  à  90  mmHg.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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There  is  a  large  body  of  epidemiological  data  concerning
the  prevalence  of  hypertension  and  its  rate  of  con-
trol  in  populations  aged  <  75  years  [1—4],  but  little  is
known  about  these  aspects  in  patients  aged  >  80  years.
One  recent  survey  estimated  the  prevalence  of  hyper-
tension  among  French  subjects  aged  ≥  80  years  at  70%
(69.7%  in  women,  70.4%  in  men)  [5].  The  HYVET  study
showed  that  a  drug-induced  decrease  in  blood  pressure
(BP)  by  17/6  mmHg  with  respect  to  placebo  was  associated
with  a  signiﬁcant  decrease  in  cardiovascular  morbidity  and
mortality  [6].
However,  the  overall  efﬁcacy  of  antihypertensive  therapy
depends  on  the  extent  to  which  blood  pressure  is  lowered
and  the  frequency  with  which  hypertension  is  controlled.  In
subjects  aged  between  18  and  75  years,  a  recent  French  sur-
vey  (ENNS  2006—2007)  reported  the  rate  of  blood  pressure
t
b
control  to  be  50.9%,  with  a  clear  difference  between  women
58.5%)  and  men  (41.8%),  and  as  a  function  of  age  (64%  in
omen  and  46.8%  in  men  aged  between  45  and  54  years  ver-
us  49.6%  in  women  and  33.9%  in  men  aged  between  65  and
4  years)  [7].
In  hypertensives  aged  >  80  years,  the  2005  and  2013
rench  recommendations,  as  well  as  2013  European  guide-
ines,  recommended  that  systolic  blood  pressure  (SBP)  be
educed  to  <  150  mmHg  [8—10],  while  the  2007  European
ociety  of  Hypertension  (ESH)/European  Society  of  Cardi-
logy  (ESC)  guidelines  aimed  at  an  SBP  level  <  140  mmHg
11]. Despite  its  considerable  socioeconomic  importance,
he  speciﬁc  issue  of  blood  pressure  control  in  patients  aged
 80  years  has  rarely  been  addressed.  We  therefore  decided
o  carry  out  this  observational  study,  to  investigate  both
he  frequency  of  patients  aged  >  80  years  with  uncontrolled
lood  pressure  and  the  management  of  these  patients  in
urrent  clinical  practice.
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ethods
his  nationwide  survey  was  carried  out  between  December
007  and  May  2008.  The  investigators  were  selected  at  ran-
om  from  a  list  of  about  15000  general  practitioners  (GPs)
nd  1500  cardiologists  throughout  France.
Each  investigator  was  asked  to  include  four  consecutive
ypertensive  patients  aged  ≥80  years  and  taking  antihy-
ertensive  medication  at  the  time  of  consultation.  All  the
atients  included  had  to  have  been  known  to  their  GP
r  cardiologist  for  several  months.  There  were  no  speciﬁc
xclusion  criteria,  but  the  doctors  had  to  include  outpa-
ients  who  were  able  to  come  to  surgery  and  to  answer  their
uestions  correctly.  Each  physician  was  asked  to  complete
 questionnaire  that  included  the  following  information
obtained  from  the  patient’s  medical  ﬁle,  direct  examina-
ion  and  medical  interview):  demographic  characteristics;
amily  history  of  cardiovascular  diseases;  smoking  sta-
us;  hypercholesterolaemia;  diabetes  mellitus;  target  organ
amage  (left  ventricular  hypertrophy  and/or  microalbu-
inuria);  established  cardiovascular  disease;  renal  disease
creatinine  clearance  <60  mL/min  according  to  Cockcroft’s
ormula  or  proteinuria  >  500  mg/day);  duration  of  hyper-
ension;  current  clinical  blood  pressure;  and  current
ntihypertensive  drug  use.  Blood  pressure  was  measured  at
 single  visit,  in  the  sitting  position,  by  the  physician,  with
is/her  usual  sphygmomanometer.  Measurements  had  to  be
one  according  to  the  World  Health  Organization  recommen-
ations  (i.e.  three  consecutive  readings  after  a  5-minute
est  time).
At  the  end  of  the  questionnaire,  physicians  gave  their
pinion  about  the  patient’s  blood  pressure  control  by  tick-
ng  a  box  to  select  one  of  the  following  two  propositions:
blood  pressure  too  high  and  should  be  lowered’  or  ‘blood
ressure  acceptable’.  Physicians  were  then  asked  to  report
heir  decisions  at  the  end  of  the  consultation:  prescription
f  self  blood  pressure  measurement  (SBPM)  or  ambula-
ory  blood  pressure  monitoring  (ABPM);  intensiﬁcation  of
ifestyle  changes;  requesting  the  advice  of  another  special-
st;  change  to  current  antihypertensive  treatment;  or  no
hange  in  treatment.  In  cases  of  treatment  modiﬁcation,
he  doctor  was  asked  to  indicate  whether  they  had  added
 drug  to  the  existing  regimen,  replaced  one  or  more  drugs
y  other  drugs  and/or  increased  the  dose  of  one  or  several
rugs.
Patients  were  informed  orally,  signed  an  informed
onsent  form  and  their  identities  were  kept  secret,  in  accor-
ance  with  French  law.  An  ‘institutional  board’  supervised
he  study.
ata analysis
s  differences  in  blood  pressure  and  cardiovascular  risk
ere  expected  between  GPs’  and  cardiologists’  patients,  all
nalyses  were  stratiﬁed  according  to  the  physician  status.
he  prevalence  of  uncontrolled  hypertension  was  calculated
ccording  to  the  available  guidelines:  percentage  of  patients
ith  SBP  ≥  150  mmHg  [8—10].  Assuming  a  prevalence  of
ncontrolled  hypertension  of  about  50%  and  a  precision  of
he  95%  conﬁdence  interval  (CI)  of  3%,  a  sample  size  of  about
000  patients  was  required  for  this  study.  For  descriptive
(
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nalyses,  means  ±  standard  deviations  are  reported  for  con-
inuous  variables  and  absolute  numbers  and  percentages  are
eported  for  categorical  variables.  The  factors  associated
ith  high  blood  pressure  and  with  the  physician’s  interpre-
ation  of  blood  pressure  results  were  identiﬁed  by  univariate
nalysis  (Student’s  t  test  for  quantitative  variables  and  chi-
quare  test  for  qualitative  variables)  and  by  multivariable
nalysis  with  a  logistic  regression  analysis  performed  using
 manual  backward  procedure.  All  the  variables  associated
ith  the  dependent  variable  in  univariate  analysis,  with  a  P
alue  <  0.20,  were  considered  in  the  maximal  model  of  the
ultivariable  analysis.  Best-ﬁt  models  obtained  after  apply-
ng  backward  procedure  contain  only  the  variables  showing
n  adjusted  P  value  <  0.05.  Analyses  were  carried  out  with
AS  version  9.2  software  (SAS  Institute,  Cary,  NC,  USA).
esults
n  total,  248  physicians  participated  in  this  study;  they
nrolled  1119  patients,  971  of  whom  could  be  evaluated
204  recruited  by  cardiologists  and  767  recruited  by  GPs).
he  main  characteristics  of  the  patients  are  presented,  as  a
unction  of  physician  status,  in  Table  1. The  most  frequently
eported  risk  factor  associated  with  hypertension  was  dyslip-
daemia,  followed  by  diabetes  mellitus  and  obesity.  Active
obacco  consumption  was  quite  low.  The  cardiology  patients
C  group)  had  a much  higher  prevalence  of  target  organ
amage  than  the  patients  consulting  GPs  (GP  group).
urrent antihypertensive treatment
atients  were  taking  a  mean  of  two  classes  of  antihyper-
ensive  drugs  (Table  2).  The  mean  number  of  classes  of
rug  used  was  higher  in  the  C  group  than  in  GP  group:
.43  ±  0.97  and  1.98  ±  0.92,  respectively.  Moreover,  44.4%
f  the  patients  in  the  C  group  were  given  drugs  from  three
r  more  classes,  versus  only  26.7%  in  the  GP  group.  Diuret-
cs  were  the  most  frequently  prescribed  antihypertensive
gents  (66%  in  the  C  group,  54%  in  the  GP  group)  followed
y  angiotensin-converting  enzyme  inhibitors  (47%  and  37%,
espectively).  Calcium  channel  blockers  were  the  third  most
requently  prescribed  class  of  drugs  in  the  C  group  (42%)  and
he  fourth  most  frequently  prescribed  class  of  drugs  in  the
P  group  (29%).  Diuretics  were  absent  from  the  drugs  pre-
cribed  to  10.9%  of  the  patients  (32/294)  taking  drugs  from
hree  or  more  different  classes  (10/90  in  the  C  group  and
2/204  in  the  GP  group).
lood pressure levels and prevalence of
ncontrolled hypertension
ean  SBP  was  about  5  mmHg  higher  in  the  C  group  than  in  the
P  group,  whereas  the  difference  between  the  two  groups
as  <  1  mmHg  for  diastolic  blood  pressure  (DBP)  (Table  3).
o  differences  in  mean  SBP  or  DBP  were  found  between  men
nd  women.The  prevalence  of  uncontrolled  hypertension  was  36.6%
95%  CI  37.8—51.4)  in  the  overall  population:  44.6%  (95%
I  37.8—51.4)  in  the  C  group  (men  43.0%;  women  46.1%)
nd  34.4%  (95%  CI  31.0—37.8)  in  the  GP  group  (men  36.4%;
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Table  1  Demographic  and  clinical  characteristics:  risk  factors  among  patients  seen  by  cardiologists  or  general
practitioners.
Patient  characteristics  C  group  GP  group  Total
(n  =  204)  (n  =  767)  (n  =  971)
Age  (years) 84.0  ±  3.2 85.0  ±  3.9a 84.8  ±  3.8
Age  group
<85 years  134  (66)  400  (42)  534  (55)
85—89  years  57  (28)  275  (36)  332  (34)
≥90  years  13  (6)  91  (12)  104  (11)
Female  sex  117  (57.6)  437  (57.8)  554  (57.8)
Hypertension  duration  >  1  year  199  (97.5)  737  (97.1)  936  (97.2)
BMI  (kg/m2)  26.89  ±  3.92  26.35  ±  4.47  26.47  ±  4.36
Obesity  (BMI  ≥30  kg/m2) 42 (20.9) 135  (18.0) 177  (18.7)
Current  smoker  13  (6.4)  53  (6.9)  66  (6.8)
Family  history  of  premature  CVD  (men  at  age  <55  years;
women  at  age  <65  years)
26  (12.7)  96  (12.5)  122  (12.6)
Dyslipidaemia  (LDL-C  ≥  1.60  g/L  and/or  HDL-C  ≤  0.40  g/L  or
treatment)
97  (47.5)  404  (52.7)  501  (51.6)
Diabetes  mellitus  57  (27.9)  175  (22.8)  232  (23.9)
Target  organ  damage  (LVH  or  abnormal  albuminuria)  84  (41.2)  154  (20.1)b 238  (24.5)
Established  CVD  (angina,  myocardial  infarction,  stroke,
peripheral  artery  disease)
91 (44.6)  311  (40.5)  402  (41.4)
Renal  disease  (creatinine  clearance  <  60  mL/min  or
proteinuria  >  500  mg/day)
37 (18.1)  109  (14.2)  146  (15.0)
Data are mean ± standard deviation or number (%). BMI: body mass index; C group: cardiologists’ patients; CVD: cardiovascular disease;
GP group: general practitioners’ patients; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; LVH:
left ventricular hypertrophy.
a P = 0.05.
b P < 0.001.
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Twomen  32.7%).  Among  these  patients  with  SPB  ≥  150  mmHg,
47%  had  a  DBP  <  90  mmHg  (54%  and  45%  in  C  and  GP  groups,
respectively)  and  received  a  more  intensive  treatment
(Table  4).  None  of  the  following  factors  was  signiﬁcantly
associated  with  poor  control:  age;  duration  of  arterial
hypertension;  body  mass  index;  various  cardiovascular  risk
factors;  diabetes;  target  organ  damage;  cardiovascular  or
renal  diseases.  Using  the  2007  ESH/ESC  cut-off  point  of
140/90  mmHg,  the  prevalence  of  uncontrolled  hypertension
reached  74.0%  in  the  C  group  (95%  CI  68.0—80.0)  and  64.4%
in  the  GP  group  (95%  CI  61.0—67.8).
Opinion of the physicians concerning blood
pressure control
The  physicians  indicated  their  opinion  of  the  blood  pressure
ﬁgures  obtained  for  963  patients  (203  in  the  C  group  and
760  in  the  GP  group).  Current  blood  pressure  ﬁgures  were
considered  too  high  for  42.4%  of  the  C  group  (86/203)  and
for  27.0%  of  the  GP  group  (205/760).
We  compared  the  doctors’  interpretation  of  the  blood
pressure  ﬁgures  with  the  objectives  deﬁned  by  2005—2013
S
m
(rench/2013  European  guidelines  for  the  very  elderly
Fig.  1).  Concordance  (SBP  <  150  mmHg  and  level  consid-
red  acceptable  or  SBP  ≥  150  mmHg  and  level  considered
oo  high)  was  found  for  >  80%  of  the  patients  in  both  the
 and  GP  groups.  Most  of  the  discrepancies  in  the  GP  group
79/103,  76.7%)  corresponded  to  patients  whose  blood  pres-
ure  was  considered  acceptable  despite  SBP  ≥  150  mmHg.
uch  patients  accounted  for  only  57.1%  of  discrepancies
20/35)  in  the  C  group.  Accordingly,  the  rate  of  satisfac-
ion  with  SBP  ≥  150  mmHg  was  22.0%  in  the  C  group  (20/91)
nd  30.4%  in  the  GP  group  (79/260).  Considering  separately
he  patients  with  SBP  ≥  150  mmHg  and  DBP  <  90  mmHg,  and
hose  with  SBP  ≥  150  mmHg  and  DBP  ≥  90  mmHg,  the  rate
f  satisfaction  was  signiﬁcantly  higher  in  the  former  group
n  =  16/49,  32.6%  in  the  C  group  and  n =  60/116,  51.7%  in  the
P  group)  than  in  the  latter  (n  =  4/42,  9.5%,  P  =  0.008  in  the
 group  and  n  =  19/144,  13.2%,  P  < 0.0001  in  the  GP  group;
able  4).Multivariable  analysis  showed  that,  after  adjustment  for
BP  level  (SBP  ≥  150  versus  <  150  mmHg),  cardiologists  were
ore  likely  to  consider  blood  pressure  to  be  acceptable
acceptable  blood  pressure  versus  too  high  and  in  need  of
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Table  2  Current  antihypertensive  treatments  among  patients  seen  by  cardiologists  or  general  practitioners.
C  group  GP  group  Total
(n  =  203a) (n  =  766a) (n  =  969)
Number  of  treatments
Single  agent 33  (16.3)  270  (35.2)  303  (31.3)
Two-drug  combination 80  (39.4) 292  (38.1)  372  (38.4)
Three-drug  combination 65  (32.0) 156  (20.4) 221  (22.8)
Combination  of  four  or  more  drugs 25  (12.4) 48  (6.3) 73  (7.5)
Antihypertensive  drug  classes
Diuretics  134  (66.0)  414  (54.0)  548  (56.5)
ACE  inhibitors  96  (47.3)  285  (37.2)  381  (39.3)
ARBs  65  (32.0)  275  (35.9)  340  (35.1)
CCBs  85  (41.9)  222  (29.0)  307  (31.7)
Beta-blockers  82  (40.4)  217  (28.3)  299  (30.9)
Alpha-blockers  10  (4.9)  48  (6.3)  58  (6.0)
Other  antihypertensive  drug  classes  22  (10.8)  58  (7.6)  80  (8.3)
Description  of  single  agents  (n  =  303)
ACE  inhibitors  6  (18.2)  67  (24.8)  73  (24.1)
ARBs  3  (9.1)  71  (26.3)  74  (24.4)
Diuretics  12  (36.4)  52  (19.3)  64  (21.1)
CCBs  6  (18.2)  41  (15.2)  47  (15.5)
Beta-blockers  3  (9.1)  26  (9.6)  29  (9.6)
Others  3  (9.1)  13  (4.8)  16  (5.3)
Description  of  two-drug  combinations  (n  =  372)
ACE  inhibitors  +  diuretics  22  (27.5)  70  (24.0)  92  (24.7)
ARBs  +  diuretics  10  (12.5)  62  (21.2)  72  (19.3)
ACE  inhibitors  +  beta-blockers  6  (7.5)  21  (7.2)  27  (7.3)
Beta-blockers  +  diuretics  7  (8.7)  17  (5.8)  24  (6.5)
ACE  inhibitors  +  CCBs  11  (13.7)  21  (7.2)  32  (8.6)
ARBs  +  CCBs  5  (6.2)  19  (6.5)  24  (6.5)
CCBs  +  diuretics  2  (2.5)  22  (7.5)  24  (6.5)
Others  63  (12.2)  60  (20.5)  123  (33.1)
Description  of  three-drug  combinations  (n  =  221)
Beta-blockers  +  ACE  inhibitors  +  diuretics  18  (27.7)  32  (20.5)  50  (22.6)
ARBs  +  diuretics  +  CCBs  10  (15.4)  27  (17.3)  37  (16.7)
ARBs  +  diuretics  +  beta-blockers  7  (10.8)  21  (13.5)  28  (12.7)
ACE  inhibitors  +  diuretics  +  CCBs  9  (13.8)  18  (11.5)  27  (12.2)
Others  21  (32.3)  58  (37.2)  79  (35.7)
Data are number (%). ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; C group: cardiologists’ patients; CCB:
calcium channel blocker; GP group: general practitioners’ patients.
a One patient with missing values in both groups.
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qowering  [referent])  in  non-diabetic  patients  (i.e.  no  dia-
etes  versus  diabetes  [referent]:  odds  ratio  [OR]  2.68,  95%
I  1.10—6.53;  P  =  0.03)  and  in  patients  with  lower  DBP  (i.e.
BP  <  90  mmHg  versus  ≥  90  mmHg  [referent]:  OR  9.80,  95%
I  3.56—27.03;  P  =  <  0.0001).
GPs  more  frequently  considered  blood  pressure  as
cceptable  in  older  patients  (i.e.  ≥  85  years  versus  < 85  years
referent]:  OR  2.39,  95%  CI  1.42—4.02;  P  =  0.001),  in  patients
ith  hypertension  of  longer  duration  (i.e.  ≥1  year  versus  <  1
ear  [referent]:  OR  6.29,  95%  CI  1.81—22.22;  p  =  0.004)
nd  in  patients  with  lower  DBP  (i.e.  DBP  <  90  mmHg  ver-
us  ≥90  mmHg  [referent]:  OR  9.09,  95%  CI  5.38—15.38;
 =  <0.0001).
t
g
Lanagement of patients
nformation  about  patient  management  was  available  for
8.8%  of  the  C  group  and  98.0%  of  the  GP  group  (Table  5).
reatment  was  changed  in  78.8%  of  the  C  group  and  in  77.1%
f  the  GP  group,  because  the  doctor  felt  that  their  blood
ressure  was  too  high  and  needed  to  be  lowered.  The  most
requent  change  was  the  addition  of  a  drug  to  the  regimen,
n  both  groups.  However,  the  addition  of  a  drug  was  less  fre-
uent  in  patients  already  taking  ≥  3  drugs  than  in  patients
aking  ≤2  drugs:  45.2%  (14/31)  vs  72.6%  (90/124)  in  the  GP
roup  and  48.1%  (13/27)  vs  67.5%  (27/40)  in  the  C  group.
ifestyle  changes  were  more  frequently  intensiﬁed  by  GPs
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Table  3  Blood  pressure  data  among  patients  seen  by  cardiologists  or  general  practitioners.
C  group  GP  group  Total
(n  =  204) (n =  767) (n  =  971)
Systolic  blood  pressure  (mmHg)  148.5  ±  18.8  143.4  ±  15.4a 144.5  ±  16.3
Diastolic  blood  pressure  (mmHg) 81.0  ±  10.1  81.8  ±  9.4  81.7  ±  9.5
Blood  pressure  levels
SBP  <  150  and  DBP  <  90  mmHg 103  (50.5) 456  (59.4) 559  (57.6)
SBP  ≥  150  and  DBP  ≥  90  mmHg 42  (20.6) 145  (18.9) 187  (19.3)
SBP  ≥  150  and  DBP  <  90  mmHg  49  (24.0)  119  (15.5)  168  (17.3)
SBP  <  150  and  DBP  ≥  90  mmHg  10  (4.9)  47  (6.1)  57  (5.9)
Data are mean ± standard deviation or number (%). C group: cardiologists’ patients; DBP: diastolic blood pressure; GP group: general
practitioners; patients; SBP: systolic blood pressure.
a P < 0.005.
Table  4  Characteristics  of  patients  with  systolic  blood  pressure  ≥150  mmHg  according  to  diastolic  blood  pressure  level.
Patient  characteristics  DBP  <  90  mmHg  DBP  ≥  90  mmHg  P
(n  =  168)  (n  =  187)
Age  (years)  84.4  ±  3.6  84.4  ±  3.6  0.99
Female  sex  87  (52.7)  110  (59.5)  0.20
SBP  (mmHg)  158.8  ±  10.6  163.6  ±  14.2  0.004
DBP  (mmHg)  79.6  ±  6.2  94.7  ±  5.7  <0.0001
Mean  number  of  treatments  2.24  (0.99)  1.94  (0.88)  0.006
Distribution  of  treatments  0.02
Single  agent  43  (25.6)  65  (34.9)
Two-drug  combination  62  (36.9)  78  (41.9)
Three-drug  combination  46  (27.4)  33  (17.7)
Combination  of  four  or  more  drugs  17  (10.1)  10  (5.4)
Blood  pressure  ﬁgures  considered  as  acceptable  76/165  (46.1)  23/186  (12.4)  <0.0001
Treatment  reinforcement  63/92  (68.5)  135/163  (82.3)  0.01
Data are mean ± standard deviation or number (%). BMI: body mass index; CVD: cardiovascular disease; DBP: diastolic blood pressure;
GP: general practitioner; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; LVH: left ventricular
hypertrophy; SBP: systolic blood pressure.
Table  5  Management  of  patients  with  a  blood  pressure  level  that  is  considered  too  high  by  the  physician.
C  group  GP  group  Total
(n  =  85)  (n  =  201)  (n  =  286)
Medication  change  67  (78.8)  155  (77.1)  222  (77.6)
Drug  addition  40  (59.7)  104  (67.1)  144  (64.9)
Drug  switching  19  (28.4)  24  (15.5)  43  (19.4)
Increase  in  dose  18  (26.9)  36  (23.2)  54  (24.3)
Strengthening  of  lifestyle  recommendations  39  (45.9)  115  (57.2)  154  (53.8)
Associated  with  a  change  in  medication  29  (74.3)  83  (72.2)  112  (72.7)
Home  blood  pressure  measurements  23  (27.1)  55  (27.4)  78  (27.3)
Associated  with  a  change  in  medication  15  (65.2)  40  (72.7)  55  (70.5)
Ambulatory  blood  pressure  measurements  17  (20.0)  14  (7.0)  31  (10.8)
Associated  with  a  change  in  medication  13  (76.5)  6  (42.8)  19  (61.3)
Specialist  advice  sought  2  (2.3)  30  (14.9)  32  (11.1)
Data are number (%). C group: cardiologists’ patients; GP group: general practitioners’ patients.
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Figure 1. Assessment of blood pressure (BP) ﬁgures by the
doctors, taking into account the objective deﬁned by systolic
BP < 150 mmHg. C: cardiologist; D: diabetes; GP: general prac-
titioner; RI: renal disease. Orange colour: BP controlled but
considered too high; blue colour: BP uncontrolled but considered
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kcceptable; brown colour: BP uncontrolled and considered too high;
ellow colour: BP controlled and considered acceptable.
han  by  cardiologists  (57.2%  vs  45.9%)  and  were  associated
ith  treatment  changes  in  >70%  of  cases.  SBPM  was  pre-
cribed  to  >25%  of  all  patients  in  both  groups,  whereas  ABPM
as  more  frequently  prescribed  by  cardiologists  than  by  GPs
20%  vs  7%).  GPs  requested  specialist  advice  for  only  14.9%  of
heir  patients,  increasing  to  30%  (15/50)  for  patients  taking
3  drugs.
As  shown  in  Table  4,  among  patients  with  an  SBP
evel  ≥150  mmHg  and  considered  to  be  too  high,  treat-
ent  was  more  often  increased  when  DBP  was  ≥  90  mmHg
135/163,  82.3%)  than  when  DBP  was  <  90  mmHg  (63/92.
8.5%;  adjusted  OR  2.08,  95%  CI  1.18—3.57;  P  =  0.01),  as  well
s  when  the  number  of  antihypertensive  drugs  was  at  least
hree  (adjusted  OR  2.00,  95%  CI  1.12—3.57).
iscussion
ittle  is  known  about  blood  pressure  control  and  arte-
ial  hypertension  management  in  patients  aged  ≥80
ears  in  France.  The  most  recent  French  surveys  have
een  population-based  studies,  including  undiagnosed  and
ntreated  hypertensive  patients  aged  <75  years  [7,12—14].
v
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sS.  Ragot  et  al.
ifferences  in  the  level  of  hypertension  control  have  been
ighlighted  between  Europe  and  North  America,  with  lower
ates  in  European  countries  than  in  the  USA  [15—17].  How-
ver,  data  about  very  elderly  are  sparse.  The  National  Health
nd  Nutrition  Examination  Survey  showed  failure  rates  of
9.5%  in  men  and  77.8%  in  women  [18]. A  primary  care
panish  study  reported  that  64.4%  of  patients  had  a  blood
ressure  level  >  140/90  mmHg.  Thus,  these  ﬁgures  are  close
o  those  we  found  using  this  threshold  (74.0%  in  the  C  group
nd  64.6%  in  the  GP  group)  [19].
The  issue  of  the  blood  pressure  level  to  be  reached  in
he  very  elderly  is  of  crucial  importance.  In  2005,  experts  of
he  French  ‘Haute  Autorité  de  santé’  suggested  that  doctors
hould  not  try  to  lower  SBP  beyond  150  mmHg  in  patients
ged  ≥  80  years,  and  that  no  more  than  three  different
rugs  should  be  given  to  such  patients  [8].  On  the  con-
rary,  the  general  recommendations  for  Europe  published  in
007  maintained  a  target  blood  pressure  of  140/90  mmHg  for
he  entire  hypertensive  population,  regardless  of  age  [11].
he  debate  remained  open  until  the  results  of  HYVET  study,
hich  randomly  allocated  3845  patients  with  an  entry  SBP
evel  ≥160  mmHg  and  a  target  SBP  level  <150  mmHg.  Blood
ressure  decreased  to  144/78  mmHg  in  treated  patients
ersus  161/84  mmHg  in  the  placebo  group,  and  this  addi-
ional  decrease  in  blood  pressure  was  associated  with  a  30%
ecrease  in  stroke  (P  =  0.055)  and  statistically  signiﬁcant
ecreases  in  congestive  heart  failure  (64%),  major  cardio-
ascular  events  (34%)  and  all-cause  death  (21%).  Therefore,
he  2009  reappraisal  of  European  guidelines  clearly  recom-
ended  prescribing  antihypertensive  treatment  to  patients
ged  >80  years  with  SBP  >  160  mmHg,  with  the  aim  of  lower-
ng  blood  pressure  to  <150  mmHg  [20].  This  recommendation
as  approved  by  both  the  new  2013  ESH  guidelines  [10]  and
he  2013  French  recommendations  [9].
Our  study  showed  that  the  high  prevalence  of  uncon-
rolled  blood  pressure  was  not  due  to  poor  knowledge
f  current  recommendations  or  to  physicians’  willingness
o  accept  high  systolic  blood  pressure  values,  as  >80%  of
atients  were  correctly  classiﬁed  as  having  acceptable  or
nacceptable  blood  pressure  based  on  the  threshold  of  an
BP  level  of  150  mmHg.  Redon  et  al.  reported  a  consis-
ent  overestimation  of  the  number  of  controlled  patients:
n  their  paper,  the  real  blood  pressure  control  rate  was  46%
n  France,  contrasting  with  a perception  of  normalized  blood
ressure  in  84%  of  patients  [21].
Diabetes  was  found  to  be  an  independent  determinant
actor  for  blood  pressure  being  considered  unsatisfac-
ory  among  cardiologists  (OR  2.68),  but  not  among  GPs,
ndicating  that  cardiologists  were  aware  of  the  need  to
educe  blood  pressure  to  slightly  lower  levels  in  diabetic
atients.  Interestingly,  a  DBP  level  <  90  mmHg  appeared  to
e  linked,  for  both  cardiologists  and  GPs,  to  a  higher  rate
f  satisfaction,  resulting  in  a  lower  frequency  of  treatment
ncrease:  these  data  suggest  that  the  high  prognostic  value
f  pulse  pressure  is  not  taken  into  account  by  physicians  in
he  management  of  their  elderly  hypertensives  (or  is  poorly
nown  about).
Eventually,  in  more  than  one  ﬁfth  of  patients  in  our  sur-
ey  with  a  blood  pressure  that  was  considered  too  high,
either  cardiologists  nor  GPs  decided  to  change  the  treat-
ent.  Such  an  attitude  has  been  widely  reported  in  previous
tudies  and  is  described  as  ‘therapeutic  inertia’,  restricted
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to  physicians  who  have  knowledge  of  the  guidelines  but  do
not  apply  them  [22].  In  primary  care  settings,  antihyper-
tensive  medication  remains  unchanged  in  more  than  60%  of
patients  who  do  not  achieve  blood  pressure  targets  [23,24].
In  patients  aged  >80  years,  doctors  may  be  reluctant  to
increase  medication  due  to  poor  knowledge  of  pulse  pres-
sure  signiﬁcance,  as  indicated  above,  but  also  due  to  a  fear
of  adverse  reactions  to  drugs.  In  one  retrospective  cohort
study  of  patients  referred  to  a  hypertension  clinic,  the  inci-
dence  of  documented  adverse  drug  reactions  reached  40%
[25].  In  addition,  a  recent  review  showed  that  antihyper-
tensive  treatment  increased  the  risk  of  severe  falls  by  2.4
[26].  By  contrast,  in  community-dwelling  elderly  patients,
hypertension  control,  with  or  without  orthostatic  hypoten-
sion,  was  not  associated  with  a  higher  risk  of  falls  [27].  In
our  survey,  some  physicians  decided  to  add  a  new  drug  to
the  treatment  regimen  of  patients  already  taking  a  three-
drug  combination  (48.1%  in  the  C  group  and  45.2%  in  the
GP  group),  despite  recommendations  to  treat  patients  aged
>80  years  with  no  more  than  three  drugs.  The  proportion  of
patients  treated  with  three  or  more  antihypertensive  drugs
was  higher  in  our  survey  than  in  the  population  from  the  USA
[18]:  20%  vs  44%  in  the  C  group  and  26%  in  the  GP  group  in
our  study.
The  new  2013  ESH  guidelines  [10]  stressed  that  ‘in  frail
elderly  patients,  it  is  recommended  to  leave  decisions  on
antihypertensive  therapy  to  the  treating  physician,  and
based  on  monitoring  of  the  clinical  effects  of  treatment’:
this  recommendation  is  in  agreement  with  the  ﬁndings  of
some  outcome-based  studies,  namely  the  JATOS  study,  which
showed  no  difference  regarding  total  deaths  between  the
strict-treatment  group  and  the  mild-treatment  group  [28].
Blood  pressure  control  could  also  be  improved  by  the  use  of
SBPM:  a  meta-analysis  conducted  by  Bray  et  al.  has  shown
SBP/DBP  ﬁgures  to  be  4.82/1.45  mmHg  lower  in  patients
enrolled  in  trials  with  SBPM  than  in  trials  without  SBPM  [29].
On  the  other  hand,  ABPM  is  well  tolerated  in  the  very  elderly
and  would  prevent  an  inappropriate  escalation  of  drug  treat-
ment  in  those  with  a  marked  white-coat  effect  [25].  The
American  College  of  Cardiology  Foundation/American  Heart
Association  consensus  on  hypertension  in  the  elderly  recom-
mends  these  ambulatory  measurements  [30].
Study limitations
Our  study  has  a  number  of  limitations.  First,  it  was  a  visit-
based  rather  than  a  population-based  survey:  patients  were
able  to  visit  the  surgery  and  to  answer  doctors’  questions,
so  our  ﬁndings  should  not  be  extrapolated  to  octogenar-
ians  with  severe  physical  and/or  cognitive  alteration  nor
to  octogenarian  inpatients  [31].  Second,  the  prevalence  of
uncontrolled  hypertension  may  have  been  overestimated
because  blood  pressure  was  measured  at  a  single  visit.  Third,
as  the  aim  of  this  survey  was  to  investigate  blood  pressure
control  under  conditions  of  daily  clinical  practice,  the  blood
pressure  device  was  not  standardized;  however  this  is  a  cur-
rent  methodological  choice  in  this  kind  of  survey  [19].Conclusions
In  conclusion,  the  frequency  of  uncontrolled  hypertension
(deﬁned  as  SBP  ≥  150  mmHg)  in  hypertensive  outpatients243
ged  ≥80  years  was  found  to  be  as  high  as  37%  in  France.
 concordance  between  the  blood  pressure  values  and  the
octor’s  interpretation  of  those  values  was  observed  in  80%
f  the  patients.  Doctors  were  satisﬁed  with  SBP  ≥  150  mmHg
n  one  in  four  patients.  The  treatment  was  changed  in
bout  80%  of  the  patients  considered  to  have  an  unsatis-
actory  blood  pressure,  whereas  it  was  modiﬁed  in  about
0%  of  those  with  SBP  >  150  mmHg,  regardless  of  the  doctor’s
nterpretation.  Diabetes  was  an  independent  determinant  of
lood  pressure  being  considered  unsatisfactory.  Our  ﬁndings
uggest  that  French  physicians  are  aware  that  SBP  should
e  lowered  to  <150  mmHg  in  the  elderly  but,  unfortunately,
re  less  likely  to  increase  treatment  in  uncontrolled  patients
ith  a  DBP  <  90  mmHg.
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